Cyclic Peptides Can Engage a Single Binding Pocket Through Highly Divergent Modes

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2020 Oct 13

PMID 33046654

Citations 16

Authors

Karishma Patel

Louise J Walport

James L Walshe

Paul D Solomon

Jason K K Low

Daniel H Tran

Kevork S Mouradian

Ana P G Silva

Lorna Wilkinson-White

Alexander Norman

Charlotte Franck

Jacqueline M Matthews

J Mitchell Guss

Richard J Payne

Toby Passioura

Hiroaki Suga

Joel P Mackay

Affiliations

Soon will be listed here.

Abstract

Cyclic peptide library screening technologies show immense promise for identifying drug leads and chemical probes for challenging targets. However, the structural and functional diversity encoded within such libraries is largely undefined. We have systematically profiled the affinity, selectivity, and structural features of library-derived cyclic peptides selected to recognize three closely related targets: the acetyllysine-binding bromodomain proteins BRD2, -3, and -4. We report affinities as low as 100 pM and specificities of up to 10-fold. Crystal structures of 13 peptide-bromodomain complexes reveal remarkable diversity in both structure and binding mode, including both α-helical and β-sheet structures as well as bivalent binding modes. The peptides can also exhibit a high degree of structural preorganization. Our data demonstrate the enormous potential within these libraries to provide diverse binding modes against a single target, which underpins their capacity to yield highly potent and selective ligands.

Citing Articles

Macrocyclic peptides as a new class of targeted protein degraders.

Jing X, Mackay J, Passioura T RSC Chem Biol. 2025; 6(3):326-337.

PMID: 39822773 PMC: 11733494. DOI: 10.1039/d4cb00199k.

Discovering covalent cyclic peptide inhibitors of peptidyl arginine deiminase 4 (PADI4) using mRNA-display with a genetically encoded electrophilic warhead.

Mathiesen I, Calder E, Kunzelmann S, Walport L Commun Chem. 2024; 7(1):304.

PMID: 39702664 PMC: 11659602. DOI: 10.1038/s42004-024-01388-9.

3D physiologically-informed deep learning for drug discovery of a novel vascular endothelial growth factor receptor-2 (VEGFR2).

Xu M, Xiao X, Chen Y, Zhou X, Parisi L, Ma R Heliyon. 2024; 10(16):e35769.

PMID: 39220924 PMC: 11365333. DOI: 10.1016/j.heliyon.2024.e35769.

Targeting the UCHL3 ubiquitin hydrolase using chemically constrained peptides.

King H, Bycroft M, Nguyen T, Kelly G, Vinogradov A, Rowling P Proc Natl Acad Sci U S A. 2024; 121(21):e2322923121.

PMID: 38739798 PMC: 11126973. DOI: 10.1073/pnas.2322923121.

Engineering tRNAs for the Ribosomal Translation of Non-proteinogenic Monomers.

Sigal M, Matsumoto S, Beattie A, Katoh T, Suga H Chem Rev. 2024; 124(10):6444-6500.

PMID: 38688034 PMC: 11122139. DOI: 10.1021/acs.chemrev.3c00894.

References

Gosmini R, Nguyen V, Toum J, Simon C, Brusq J, Krysa G . The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor. J Med Chem. 2014; 57(19):8111-31. DOI: 10.1021/jm5010539. View

Olp M, Sprague D, Goetz C, Kathman S, Wynia-Smith S, Shishodia S . Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites. ACS Chem Biol. 2020; 15(4):1036-1049. PMC: 7271629. DOI: 10.1021/acschembio.0c00058. View

Morimoto J, Hayashi Y, Suga H . Discovery of macrocyclic peptides armed with a mechanism-based warhead: isoform-selective inhibition of human deacetylase SIRT2. Angew Chem Int Ed Engl. 2012; 51(14):3423-7. DOI: 10.1002/anie.201108118. View

Matsunaga Y, Bashiruddin N, Kitago Y, Takagi J, Suga H . Allosteric Inhibition of a Semaphorin 4D Receptor Plexin B1 by a High-Affinity Macrocyclic Peptide. Cell Chem Biol. 2016; 23(11):1341-1350. DOI: 10.1016/j.chembiol.2016.09.015. View

Lamonica J, Deng W, Kadauke S, Campbell A, Gamsjaeger R, Wang H . Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes. Proc Natl Acad Sci U S A. 2011; 108(22):E159-68. PMC: 3107332. DOI: 10.1073/pnas.1102140108. View

Law R, Atkinson S, Bamborough P, Chung C, Demont E, Gordon L . Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain. J Med Chem. 2018; 61(10):4317-4334. DOI: 10.1021/acs.jmedchem.7b01666. View

Lucas X, Wohlwend D, Hugle M, Schmidtkunz K, Gerhardt S, Schule R . 4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew Chem Int Ed Engl. 2013; 52(52):14055-9. DOI: 10.1002/anie.201307652. View

Gilan O, Rioja I, Knezevic K, Bell M, Yeung M, Harker N . Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Science. 2020; 368(6489):387-394. PMC: 7610820. DOI: 10.1126/science.aaz8455. View

Gerona-Navarro G, Yoel-Rodriguez , Mujtaba S, Frasca A, Patel J, Zeng L . Rational design of cyclic peptide modulators of the transcriptional coactivator CBP: a new class of p53 inhibitors. J Am Chem Soc. 2011; 133(7):2040-3. PMC: 3047509. DOI: 10.1021/ja107761h. View

10.

Fujisawa T, Filippakopoulos P . Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. Nat Rev Mol Cell Biol. 2017; 18(4):246-262. DOI: 10.1038/nrm.2016.143. View

11.

French C, Miyoshi I, Kubonishi I, Grier H, Perez-Atayde A, Fletcher J . BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res. 2003; 63(2):304-7. View

12.

Gamsjaeger R, Webb S, Lamonica J, Billin A, Blobel G, Mackay J . Structural basis and specificity of acetylated transcription factor GATA1 recognition by BET family bromodomain protein Brd3. Mol Cell Biol. 2011; 31(13):2632-40. PMC: 3133386. DOI: 10.1128/MCB.05413-11. View

13.

Walport L, Obexer R, Suga H . Strategies for transitioning macrocyclic peptides to cell-permeable drug leads. Curr Opin Biotechnol. 2017; 48:242-250. DOI: 10.1016/j.copbio.2017.07.007. View

14.

Alqahtani A, Choucair K, Ashraf M, Hammouda D, Alloghbi A, Khan T . Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Future Sci OA. 2019; 5(3):FSO372. PMC: 6426170. DOI: 10.4155/fsoa-2018-0115. View

15.

Sakai K, Passioura T, Sato H, Ito K, Furuhashi H, Umitsu M . Macrocyclic peptide-based inhibition and imaging of hepatocyte growth factor. Nat Chem Biol. 2019; 15(6):598-606. DOI: 10.1038/s41589-019-0285-7. View

16.

Tsiamantas C, Otero-Ramirez M, Suga H . Discovery of Functional Macrocyclic Peptides by Means of the RaPID System. Methods Mol Biol. 2019; 2001:299-315. DOI: 10.1007/978-1-4939-9504-2_14. View

17.

Goldbach L, Vermeulen B, Caner S, Liu M, Tysoe C, van Gijzel L . Folding Then Binding vs Folding Through Binding in Macrocyclic Peptide Inhibitors of Human Pancreatic α-Amylase. ACS Chem Biol. 2019; 14(8):1751-1759. PMC: 6700688. DOI: 10.1021/acschembio.9b00290. View

18.

Kawamura A, Munzel M, Kojima T, Yapp C, Bhushan B, Goto Y . Highly selective inhibition of histone demethylases by de novo macrocyclic peptides. Nat Commun. 2017; 8:14773. PMC: 5384220. DOI: 10.1038/ncomms14773. View

19.

Perez-Salvia M, Esteller M . Bromodomain inhibitors and cancer therapy: From structures to applications. Epigenetics. 2016; 12(5):323-339. PMC: 5453193. DOI: 10.1080/15592294.2016.1265710. View

20.

Obexer R, Walport L, Suga H . Exploring sequence space: harnessing chemical and biological diversity towards new peptide leads. Curr Opin Chem Biol. 2017; 38:52-61. DOI: 10.1016/j.cbpa.2017.02.020. View